GLMDGalmed Pharmaceuticals Ltd
GLMD
Galmed Pharmaceuticals Ltd7,504
Mkt Cap
$4.23MVolume
80,028.0052W High
$3.5052W Low
$0.7311PE Ratio
-0.22GLMD Fundamentals
Price
$0.7711Prev Close
$0.7835Open
$0.7650D MA
$0.9573Beta
1.34Avg. Volume
148,733.77EPS (Annual)
-$8.08P/B
0.22Rev/Employee
$0.00Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting PR...
PR Newswire·1mo ago
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH Galmed Announces Grant of New Use Patents for the combination...
PR Newswire·2mo ago
Galmed Issues CEO Letter to Shareholders
Galmed Issues CEO Letter to Shareholders Galmed Issues CEO Letter to Shareholders PR Newswire TEL AVIV, Israel, Dec. 1, 2025 TEL AVIV, Israel, Dec. 1, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd...
PR Newswire·2mo ago
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update PR...
PR Newswire·2mo ago
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine PR Newswire RAMAT-GAN...
PR Newswire·2mo ago
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro Galmed...
PR Newswire·2mo ago
Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update PR...
PR Newswire·5mo ago
<
...
1
>